Clinical efficacy of IgM-enriched immunoglobulin as adjunctive therapy in neonatal and pediatric sepsis: a systematic review and meta-analysis
Frontiers in Pediatrics · 11.08.2023 · 11
DOI: 10.3389/fped.2023.1239014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pediatrics, online erschienen am 11.08.2023. Verfasst von Ener Cagri Dinleyici und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Türkiye. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis is a major cause of mortality and morbidity globally, with around one-quarter of all sepsis-related deaths occurring in children under the age of 5. We conducted a meta-analysis and systematic review of the literature to evaluate the clinical effectiveness of an IgM-enriched immunoglobulin preparation in pediatrics patients and neonates with sepsis.
Methods
Systematic searches of PubMed, the Cochrane Library and Embase databases were performed in November 2022, with no date limitations, to identify studies in which IgM-enriched immunoglobulin was used as adjunctive therapy in neonatal and pediatric patients with sepsis.
Results
In total, 15 studies fulfilled the eligibility criteria, 13 neonatal studies and 2 pediatric studies. Pooled estimates from all studies indicated that mortality rates were significantly lower in patients who received treatment with the IgM-enriched immunoglobulin compared with controls (OR 0.41; 95% CI 0.32–0.55). Further analyses in neonatal studies, alone, showed a significant benefit with longer treatment durations (>3 days) vs. the recommended treatment duration (3 days) (OR 0.32; 95% CI 0.22–0.47) vs. (OR 0.61; 95% CI 0.41–0.92). Treatment with IgM-enriched immunoglobulin was associated with a lower mortality risk compared with controls in prospective studies vs. retrospective analyses (OR 0.37; 95% CI 0.27–0.51) vs. (OR 0.73; 95% CI 0.41–1.30).
Conclusions
This systematic review suggests that adjunctive treatment with IgM-enriched immunoglobulin may reduce the risk of mortality in neonatal and pediatric populations. However, large randomized controlled trials are required to further substantiate and evaluate these findings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Eskisehir Osmangazi University Faculty of Medicine, Eskisehir, Türkiye.
- Klinik für Neonatologie, Darmstädter Kinderkliniken Prinzessin Margaret, Perinatalzentrum Südhessen, Darmstadt, Germany.
- Pediatric Intensive Care Unit, University Hospital Center "Mother Teresa", Tirana, Albania.
- Corporate Medical Affairs, Biotest AG, Dreieich, Germany.
- Corporate Clinical Research & Development, Biotest AG, Dreieich, Germany.
- Medical and Scientific Affairs, Biotest UK, Birmingham, United Kingdom.
Zitieren
APA
Dinleyici, E. C., Frey, G., Kola, E., Wippermann, U., Bauhofer, A., Staus, A., Griffiths, P., Azharry, M., & Rohsiswatmo, R. (2023). Clinical efficacy of IgM-enriched immunoglobulin as adjunctive therapy in neonatal and pediatric sepsis: a systematic review and meta-analysis. Frontiers in Pediatrics, 11. https://doi.org/10.3389/fped.2023.1239014
Vancouver
Dinleyici EC, Frey G, Kola E, Wippermann U, Bauhofer A, Staus A, et al. Clinical efficacy of IgM-enriched immunoglobulin as adjunctive therapy in neonatal and pediatric sepsis: a systematic review and meta-analysis. Frontiers in Pediatrics. 2023;11. doi:10.3389/fped.2023.1239014
BibTeX
@article{Dinleyici2023,
author = {Dinleyici, Ener Cagri and Frey, Georg and Kola, Ermira and Wippermann, Ulrike and Bauhofer, Artur and Staus, Alexander and Griffiths, Peter and Azharry, Muhamad and Rohsiswatmo, Rinawati},
title = {Clinical efficacy of IgM-enriched immunoglobulin as adjunctive therapy in neonatal and pediatric sepsis: a systematic review and meta-analysis},
journal = {Frontiers in Pediatrics},
year = {2023},
volume = {11},
doi = {10.3389/fped.2023.1239014}
}
EUVIMED